Thursday, September 21, 2017

US FDA News: Ocaliva (obeticholic acid): Drug Safety Communication - Increased Risk of Serious Liver Injury

Reports of Ocaliva being incorrectly dosed in some patients with moderate to severe decreases in liver function. Some patients received a higher frequency of dosing than is recommended in the drug label.
Read more: Ocaliva (obeticholic acid): Drug Safety Communication - Increased Risk of Serious Liver Injury